Acurx Pharmaceuticals, Inc.
ACXP Nasdaq
SEC CIK 1736243
Follow Acurx Pharmaceuticals
Weekly email: filings, results
Net income
−$2.6M
−29.6% vs same quarter last year
EPS, diluted
−$0.49
+60.2% vs same quarter last year
Operating cash flow
−$2.5M
−32.3% vs same quarter last year
Operating income
−$2.6M
−29.7% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$8M |
| FY24 | −$14.1M |
| FY23 | −$14.6M |
| FY22 | −$12.1M |
| FY21 | −$12.7M |
| FY20 | −$4.6M |
| FY19 | - |